Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
99 hedge funds and large institutions have $1.03B invested in Apellis Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 13 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 21
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
31% more capital invested
Capital invested by funds: $783M → $1.03B (+$242M)
8% more funds holding
Funds holding: 92 → 99 (+7)
0% more call options, than puts
Call options by funds: $1.91M | Put options by funds: $1.9M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7.34% less ownership
Funds ownership: 71.35% → 64% (-7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.8M |
| 2 |
BlackRock
New York
|
+$15.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.7M |
| 4 |
Jennison Associates
New York
|
+$6.83M |
| 5 |
Goldman Sachs
New York
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$25.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.9M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$10.7M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$7.11M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.17M |
APLS Hedge Fund Activity: Q2 2019 in Review
99 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2019, worth a combined $1.03B — up 31% from $783M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new APLS positions and 13 closed out — a net gain of 9 holders — while 46 added to existing stakes and 21 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $25.8M. The largest seller was Morgan Stanley, cutting an estimated $25.2M.
- 99 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2019, up from 92 in Q1 2019.
- Funds reported $1.03B of Apellis Pharmaceuticals stock for Q2 2019, up 31% quarter-over-quarter.
- 22 funds opened new Apellis Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +9 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2019 was Wellington Management Group, an estimated $25.8M added.
- The largest Apellis Pharmaceuticals seller in Q2 2019 was Morgan Stanley, an estimated $25.2M sold.
Based on aggregated 13F filings for Q2 2019.